Compare AbbVie Inc (ABBV) vs Oxford Lane Capital Corp (OXLC) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

OXLC trades at $8.95, up 1.59% today, with a bullish technical signal but mixed indicators. The stock shows a P/B of 0.85, suggesting potential undervaluation, but profitability metrics are weak with a -39.16% ROE. Recent earnings have consistently missed expectations, including a significant Q1 2026 EPS miss. The company maintains a regular dividend payout of $0.20 per share, supporting income-focused investors despite fundamental challenges.

Outlook remains cautious due to persistent earnings underperformance and negative ROE/ROA. High dividend yield attracts income seekers, but sustainability concerns and NAV declines pose risks. Analyst consensus is divided, with 50% buy ratings balanced by bearish sentiment from financial media. Key risks include further NAV erosion and reliance on financing cash flows.